Quantitative analysis of tumor size in a murine model of retinoblastoma

Ophthalmic Genetics

Volumn 30, Issue 2, 2009, Pages 84-90

  Dimaras, Helen ^a,b   Marchong, Mellone N ^a,b   Gallie, Brenda L ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Digital slide scanning; Retina; Retinoblastoma; TAg RB; Tumor quantification

Indexed keywords

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFACT; CANCER MODEL; COMPUTER ANALYSIS; DIGITAL IMAGING; EARLY CANCER; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINOBLASTOMA; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMAGE PROCESSING; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; RETINA TUMOR; VISUAL SYSTEM EXAMINATION;

MURINAE;

RETINOBLASTOMA PROTEIN; VIRUS T ANTIGEN;

ANIMALS; ANTIGENS, VIRAL, TUMOR; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DISEASE MODELS, ANIMAL; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RETINAL NEOPLASMS; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN;

EID: 65449186297     PISSN: 13816810     EISSN: 17445094     Source Type: Journal    
DOI: 10.1080/13816810902721439     Document Type: Article

References (34)

1. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res. 1999;59:1731s-1735s.
2. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46:617-634.
3. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005;24:4741-4753.
4. Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer. 2006;45:72-82.
5. Grasemann C, Gratias S, Stephan H, Schuler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F, Eggert A, Lohmann DR. Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene. 2005;24:6441-6449.
6. Marchong MN, Chen D, Corson TW, Lee C, Harmandayan M, Bowles E, Chen N, Gallie BL. Minimal 16q genomic loss implicates cadherin-11 in retinoblastoma. Mol Cancer Res. 2004;2:495-503.
7. Dimaras H, Coburn B, Pajovic S, Gallie BL. Loss of p75 neurotrophin receptor expression accompanies malignant progression to human and murine retinoblastoma. Mol Carcinog. 2006;45:333-343.
8. Dimaras H, Gallie BL. The p75 NTR neurotrophin receptor is a tumor suppressor in human and murine retinoblastoma development. Int J Cancer. 2008;122:2023-2029.
9. Pacal M, Bremner R. Insights from animal models on the origins and progression of retinoblastoma. Curr Mol Med. 2006;6:759-781.
10. Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell. 2004;5:539-551.
11. Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle. 2004;3:952-959.
12. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev. 2004;18:1681-1694.
13. Windle JJ, Albert DM, O'Brien JM, Marcus DM, Disteche CM, Bernards R, Mellon PL. Retinoblastoma in transgenic mice. Nature. 1990;343:665-669.
14. Albert DM, Kumar A, Strugnell SA, Darjatmoko SR, Lokken JM, Lindstrom MJ, Patel S. Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models. Arch Ophthalmol. 2004;122:1357-1362.
15. Escalona-Benz E, Jockovich ME, Murray TG, Hayden B, Hernandez E, Feuer W, Windle JJ. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2005;46:8-11.
16. Tong CT, Howard SA, Shah HR, Van Quill KR, Lin ET, Grossniklaus HE, O'Brien JM. Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma. Br J Ophthalmol. 2005;89:1217-1220.
17. Jockovich ME, Murray TG, Escalona-Benz E, Hernandez E, Feuer W. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Invest Ophthalmol Vis Sci. 2006;47:1264-1268.
18. Robanus-Maandag E, Dekker M, Van Der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A, te Riele H. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev.1998;12:1599-1609.
19. Macpherson D, Conkrite K, Tam M, Mukai S, Mu D, Jacks T. Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. Embo J. 2007;26:784-794.
20. Vooijs M, Te Riele H, Van Der ValkM, Berns A. Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells. Oncogene. 2002;21:4635-4645.
21. Van Quill KR, Dioguardi PK, Tong CT, Gilbert JA, Aaberg TM, Jr., Grossniklaus HE, EdelhauserHF, O'Brien JM. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology. 2005;112:1151-1158.
22. Abbey CK, Borowsky AD, Gregg JP, Cardiff RD, Cherry SR. Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography. JMammary Gland Biol Neoplasia. 2006;11:137-149.
23. Raman V, Pathak AP, Glunde K, Artemov D, Bhujwalla ZM. Magnetic resonance imaging and spectroscopy of transgenic models of cancer. NMR Biomed. 2007;20:186-199.
24. Marchong MN. Identification of CDH11 as a Candidate Tumor Suppressor in Retinoblastoma and Characterization of its role in Retina and Retinoblastoma. Medical Biophysics, Ph.D. dissertation. Toronto: University of Toronto, 2007.
25. LeeKF, Li E, Huber LJ, Landis SC, Sharpe AH, ChaoMV, Jaenisch R. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell. 1992;69:737-749.
26. Von Schack D, Casademunt E, Schweigreiter R, Meyer M, Bibel M, Dechant G. Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. Nat Neurosci. 2001;4:977-978.
27. Horikawa K, Radice G, Takeichi M, Chisaka O. Adhesive subdivisions intrinsic to the epithelial somites. Dev Biol. 1999;215:182-189.
28. Fischer AJ, Reh TA. Potential ofMuller glia to become neurogenic retinal progenitor cells. Glia. 2003;43:70-76.
29. Walcott JC, Provis JM. Muller cells express the neuronal progenitor cell marker nestin in both differentiated and undifferentiated human foetal retina. Clin Experiment Ophthalmol. 2003;31:246-249.
30. Mancuso K, Hendrickson AE, Connor TB, Jr., Mauck MC, Kinsella JJ, Hauswirth WW, Neitz J, Neitz M. Recombinant adenoassociated virus targets passenger gene expression to cones in primate retina. J Opt Soc Am A 2007;24:1411-1416.
31. Kocaoglu OP, Uhlhorn SR, Hernandez E, Juarez RA,Will R, Parel JM, Manns F. Simultaneous fundus imaging and optical coherence tomography of the mouse retina. Invest Ophthalmol Vis Sci. 2007;48:1283-1289.
32. Brown AS, Leamen L, Cucevic V, Foster FS. Quantitation of hemodynamic function during developmental vascular regression in the mouse eye. Invest Ophthalmol Vis Sci. 2005;46:2231-2237.
33. Foster FS, Zhang M, Duckett AS, Cucevic V, Pavlin CJ. In vivo imaging of embryonic development in the mouse eye by ultrasound biomicroscopy. Invest Ophthalmol Vis Sci. 2003;44:2361-2366.
34. Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Dev. 2007;10:167-175.